NCT06240754View on ClinicalTrials.gov

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

June 30, 2027

Conditions

Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined Significance

Interventions

DRUG

Enasidenib

Provided by BMS.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Damon Runyon Cancer Research Foundation

OTHER

lead

Washington University School of Medicine

OTHER